2498. Package #№240.2 (ANA. Sjogren's syndrome (SS), quantitative determination, IgG antibodies)

Panel No. 240.2 “ANA Test for Sjögren’s Syndrome (SS)” is a quantitative test for IgG antinuclear antibodies used to diagnose autoimmune involvement of the exocrine glands. The test has high sensitivity for primary Sjögren’s syndrome but may also be positive in rheumatoid arthritis and systemic lupus erythematosus.

The detection of specific ANA is associated with mucosal dryness and involvement of the joints, lungs, kidneys, and nervous system.

The panel includes quantitative determination of IgG antibodies to SS-B/La and SS-A/Ro antigens using the EliA method.

Anti-SS-A (Ro) antibodies are directed against proteins associated with Y1–Y5 RNA within the spliceosome. These antibodies are most commonly detected in Sjögren’s syndrome and systemic lupus erythematosus. In SLE, their production is associated with a specific set of clinical manifestations and laboratory abnormalities, including photosensitivity, Sjögren’s syndrome, and increased production of rheumatoid factor.

The presence of anti-SS-A antibodies in the blood of a pregnant woman is associated with a high risk of neonatal lupus syndrome in the infant.

Anti-SS-B (La) antibodies, directed against proteins associated with RNA polymerase III, are detected in 40–50% of patients with Sjögren’s disease. They may also be detected in patients with systemic lupus erythematosus (SLE) with late-onset disease. In such cases, the presence of these antibodies is considered to be associated with a relatively low frequency of lupus nephritis.

• For screening for autoimmune diseases in patients with dry eyes, dry mouth, or skin manifestations.
• For monitoring disease course and assessing treatment efficacy.
• For the differential diagnosis of primary and secondary Sjögren’s syndrome.

• Venous blood

In order to exclude factors that may affect the test results, we recommend to follow the preparation rules: